Unleashing Zika virus (ZIKV) against glioblastoma

Glioblastoma is the most common malignant brain tumor in both adults and children. Although they are derived from astrocytes, these tumors are characterized by heterogeneous cellularity, including a cell population that possesses other features common to cancer stem cells. As glioblastoma is incurable with present therapies, there is growing interest in oncolytic virotherapy to target GSCs as part of a combined treatment regimen.
Based on the observation that ZIKV targets neural precursor cells and yet has fewer nocuous effects on the adult versus fetal brain. The study Zhu et al investigated the actions of ZIKV infection on glioblastoma in vitro as well as in vivo. The authors found that ZIKV preferentially infected and killed GSCs compared to differentiated glioma cells in cultured cells and organoids, in contrast to West Nile Virus’ more indiscriminate killing. In addition, glioblastoma mouse models showed that ZIKV infection attenuated tumor growth and extended animal survival. Taken together, this study represents a first step in the potential use of modified ZIKV to combat glioblastoma.

This article duplicated from: http://www.genetex.com

No corresponding comment